# The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation

> **NCT04377750** · PHASE4 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 500 (estimated)

## Conditions studied

- Covid19 Pneumonia

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04377750
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-08
- **Primary completion:** 2020-04-29
- **Final completion:** 2021-05-08
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2020-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377750, "The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04377750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*